Curi Bio
Curi Bio provides integrated platforms that combine advanced 3D human tissue models, biosystems for functional analysis, and AI-enabled data analytics to support drug discovery and preclinical R&D. Its products and services are used by pharmaceutical and biotechnology companies to improve the predictive accuracy of drug safety, efficacy, and potency assessments, with a focus on cardiac, skeletal muscle, and disease models. The organization aims to accelerate the development of next-generation human medicines by integrating human cells, systems, and data.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2015
- Type
- Corporation Seattle business license
- Employees
- 51
- Registered name
- Nanosurface Biomedical Inc Seattle business license
- Stage
- Series B
- Founders
- Elliot Fisher
Is this your organization? Claim it
Curi Bio closes $10M oversubscribed Series A led by Dynamk Capital with new investors UTC Investment and DS Asset Management
Curi Bio closed a $10M oversubscribed Series A second closing to scale its human stem cell–based Curi Engine and Mantarray platforms, aiming to accelerate development of 3D engineered muscle tissue models for drug discovery.
People
-
Elliot Fisher Co-Founder & Chief Business Officer
-
Michael Cho Executive, Chief Strategy Officer
-
Nicholas Geisse Executive, Chief Executive Officer